SCHEMBL10299809

SCHEMBL10299809

CCS(=O)(=O)Nc1sc2ccccc2c1C=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSIP1 O75475 1/20 0.41
▸ HPGD P15428 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ ABCC1 P33527 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.36
▸ ACLY P53396 1/20 0.35
▸ PADI4 Q9UM07 1/20 0.35
▸ NR3C2 P08235 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099587 0.77 ACLY (0.47) PSIP1HPGDLMNAKDM4EGAA
SCHEMBL23303025 0.72 CNR2 (0.46) GAAALDH1A1PADI4GPR3CYP2A6
SCHEMBL11888064 0.71 HSD11B1 (0.38) LMNAMAPTALDH1A1ABCC1ABCG2
SCHEMBL1160897 0.70 HSD11B1 (0.36) MAPTALDH1A1ABCC1ABCG2ACLY
SCHEMBL1093585 0.70 GPR3 (0.44) HPGDLMNAHTTSMN1; SMN2KDM4E
SCHEMBL2061089 0.68 HSD11B1 (0.39) LMNAMAPTALDH1A1ABCC1ABCG2
SCHEMBL2061560 0.68 HSD11B1 (0.42) LMNAGAAMAPTMEN1ALDH1A1
SCHEMBL19225704 0.68 GPR3 (0.46) HPGDLMNASMN1; SMN2KDM4EMAPT
SCHEMBL843065 0.68 GPR3 (0.46) HPGDLMNAHTTSMN1; SMN2KDM4E
SCHEMBL10280855 0.67 HSD11B1 (0.50) LMNAMAPTABCC1ABCG2ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8216547-B2 Radiolabelled TRP M8 receptor ligands JANSSEN PHARMACEUTICA NV (BE) 2012-07-10 — — US disclosed
US-8216547-B2 Radiolabelled TRP M8 receptor ligands JANSSEN PHARMACEUTICA NV (BE) 2012-07-10 — — US disclosed
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 — — US disclosed
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 — — US disclosed
WO-2010009220-A2 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS TRPM8, TRPM7, GPR68 PSIP1 3684/4885HPGD 4048/4885LMNA 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback